Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 137


Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.

Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O.

Future Oncol. 2018 Jun 21. doi: 10.2217/fon-2018-0087. [Epub ahead of print]


Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.

Regan JN, Mikesell C, Reiken S, Xu H, Marks AR, Mohammad KS, Guise TA, Waning DL.

Front Endocrinol (Lausanne). 2017 Dec 19;8:358. doi: 10.3389/fendo.2017.00358. eCollection 2017.


Breaking Down Barriers to Chemoresistance: Role of Chemotherapy-Induced Osteoblastic Jagged1.

Mohammad KS, Guise TA.

Cancer Cell. 2017 Dec 11;32(6):717-718. doi: 10.1016/j.ccell.2017.11.016.


Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis.

Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA.

Oncotarget. 2017 Sep 23;8(49):86447-86462. doi: 10.18632/oncotarget.21200. eCollection 2017 Oct 17.


Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells.

Singh P, Hoggatt J, Kamocka MM, Mohammad KS, Saunders MR, Li H, Speth J, Carlesso N, Guise TA, Pelus LM.

J Clin Invest. 2017 Dec 1;127(12):4527-4540. doi: 10.1172/JCI94687. Epub 2017 Nov 13.


Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack J, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN.

Cancer Res. 2017 Nov 15;77(22):6299-6312. doi: 10.1158/0008-5472.CAN-17-1225. Epub 2017 Aug 30.


The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm.

Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, Mohammad KS, Zhou H, Seibel MJ, Guise TA.

Oncotarget. 2017 Apr 18;8(16):26687-26701. doi: 10.18632/oncotarget.15803.


The Role of TGFβ in Bone-Muscle Crosstalk.

Regan JN, Trivedi T, Guise TA, Waning DL.

Curr Osteoporos Rep. 2017 Feb;15(1):18-23. doi: 10.1007/s11914-017-0344-5. Review.


Differential Bone Loss in Mouse Models of Colon Cancer Cachexia.

Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG, Zimmers TA.

Front Physiol. 2017 Jan 11;7:679. doi: 10.3389/fphys.2016.00679. eCollection 2016.


Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.

Oncotarget. 2017 Jan 31;8(5):8406-8419. doi: 10.18632/oncotarget.14139.


Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.

Zhang P, Xing C, Rhodes SD, He Y, Deng K, Li Z, He F, Zhu C, Nguyen L, Zhou Y, Chen S, Mohammad KS, Guise TA, Abdel-Wahab O, Xu M, Wang QF, Yang FC.

Stem Cell Reports. 2016 Jun 14;6(6):914-925. doi: 10.1016/j.stemcr.2016.04.013. Epub 2016 May 26.


Hypercalcemia of Malignancy: A New Twist on an Old Problem.

Mohammad KS, Guise TA.

J Oncol Pract. 2016 May;12(5):435-6. doi: 10.1200/JOP.2016.012062. No abstract available.


Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling.

Regan JN, Waning DL, Guise TA.

Semin Cell Dev Biol. 2016 Jan;49:24-9. doi: 10.1016/j.semcdb.2015.11.007. Epub 2015 Nov 24. Review.


Calcium release channel RyR2 regulates insulin release and glucose homeostasis.

Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D'Ascia SL, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR.

J Clin Invest. 2015 Nov 2;125(11):4316. doi: 10.1172/JCI84937. Epub 2015 Nov 2. No abstract available.


Excess TGF-β mediates muscle weakness associated with bone metastases in mice.

Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, Zhen G, Wang X, Cao X, Roodman GD, Marks AR, Guise TA.

Nat Med. 2015 Nov;21(11):1262-1271. doi: 10.1038/nm.3961. Epub 2015 Oct 12.


Elevated incidence of fractures in women with invasive breast cancer.

Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA.

Osteoporos Int. 2016 Feb;27(2):499-507. doi: 10.1007/s00198-015-3246-3. Epub 2015 Aug 21.


TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Stayrook KR, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL, Guise TA.

Bonekey Rep. 2015 Jul 8;4:719. doi: 10.1038/bonekey.2015.88. eCollection 2015.


Corrigendum: Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin.

Wu C, Rankin EB, Castellini L, Alcudia JF, LaGory EL, Andersen R, Rhodes SD, Wilson TL, Mohammad KS, Castillo AB, Guise TA, Schipani E, Giaccia AJ.

Genes Dev. 2015 Jun 1;29(11):1202. No abstract available.


Cancer-associated muscle weakness: What's bone got to do with it?

Waning DL, Guise TA.

Bonekey Rep. 2015 May 20;4:691. doi: 10.1038/bonekey.2015.59. eCollection 2015. Review.


The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA.

Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015 May 14.

Supplemental Content

Loading ...
Support Center